186 related articles for article (PubMed ID: 30627802)
1. Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4.
Ghassabian S; Gillani TB; Rawling T; Crettol S; Nair PC; Murray M
AAPS J; 2019 Jan; 21(2):15. PubMed ID: 30627802
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib.
Murray M; Gillani TB; Rawling T; Nair PC
AAPS J; 2019 Oct; 21(6):107. PubMed ID: 31637538
[TBL] [Abstract][Full Text] [Related]
3. Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite.
Nair PC; Gillani TB; Rawling T; Murray M
Chem Biol Interact; 2021 Apr; 338():109401. PubMed ID: 33556367
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
[TBL] [Abstract][Full Text] [Related]
5. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.
Ghassabian S; Rawling T; Zhou F; Doddareddy MR; Tattam BN; Hibbs DE; Edwards RJ; Cui PH; Murray M
Biochem Pharmacol; 2012 Jul; 84(2):215-23. PubMed ID: 22513143
[TBL] [Abstract][Full Text] [Related]
6. beta-caryophyllene oxide and trans-nerolidol affect enzyme activity of CYP3A4 - in vitro and in silico studies.
Špičáková A; Bazgier V; Skálová L; Otyepka M; Anzenbacher P
Physiol Res; 2019 Nov; 68(Suppl 1):S51-S58. PubMed ID: 31755290
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Murray M; Gillani TB; Ghassabian S; Edwards RJ; Rawling T
Eur J Pharm Sci; 2018 Mar; 114():55-63. PubMed ID: 29223619
[TBL] [Abstract][Full Text] [Related]
8. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
Murray M; Zhang WV; Edwards RJ
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
[TBL] [Abstract][Full Text] [Related]
9. Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4.
Nair PC; McKinnon RA; Miners JO
Drug Metab Dispos; 2019 Jun; 47(6):616-631. PubMed ID: 30902802
[TBL] [Abstract][Full Text] [Related]
10. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics simulation and in vitro evaluation of herb-drug interactions involving dietary polyphenols and CDK inhibitors in breast cancer chemotherapy.
Patil PH; Birangal S; Shenoy GG; Rao M; Kadari S; Wankhede A; Rastogi H; Sharma T; Pinjari J; Puralae Channabasavaiah J
Phytother Res; 2022 Oct; 36(10):3988-4001. PubMed ID: 35778986
[TBL] [Abstract][Full Text] [Related]
12. Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation.
Niwa T; Yasumura M; Murayama N; Yamazaki H
Drug Metab Lett; 2014; 8(1):43-50. PubMed ID: 24484539
[TBL] [Abstract][Full Text] [Related]
13. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
[TBL] [Abstract][Full Text] [Related]
14. Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.
Foo WY; Tay HY; Chan EC; Lau AJ
Biochem Pharmacol; 2015 Oct; 97(3):320-30. PubMed ID: 26239802
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone inhibits 1α,25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitro.
Deb S; Chin MY; Adomat H; Guns ES
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():50-8. PubMed ID: 24269662
[TBL] [Abstract][Full Text] [Related]
16. VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
Zetterberg C; Maltais F; Laitinen L; Liao S; Tsao H; Chakilam A; Hariparsad N
Drug Metab Dispos; 2016 Aug; 44(8):1286-95. PubMed ID: 27298338
[TBL] [Abstract][Full Text] [Related]
17. Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells.
Wu JJ; Ge GB; He YQ; Wang P; Dai ZR; Ning J; Hu LH; Yang L
AAPS J; 2016 Jan; 18(1):134-45. PubMed ID: 26361765
[TBL] [Abstract][Full Text] [Related]
18. Use of In Vitro and Predictive In Silico Models to Study the Inhibition of Cytochrome P4503A by Stilbenes.
Basheer L; Schultz K; Fichman M; Kerem Z
PLoS One; 2015; 10(10):e0141061. PubMed ID: 26485399
[TBL] [Abstract][Full Text] [Related]
19. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
[TBL] [Abstract][Full Text] [Related]
20. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
Sutton D; Butler AM; Nadin L; Murray M
J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
